N-(3-Cyano-4,5,6,7-tetrahydro-1-benzothien-2-yl)amides as potent, selective, inhibitors of JNK2 and JNK3

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 5, 2007, Pages 1296-1301

  Angell, Richard M ^a   Atkinson, Francis L ^a   Brown, Murray J ^a   Chuang, Tsu Tshen ^a   Christopher, John A ^a   Cichy Knight, Maria ^b   Dunn, Allison K ^b   Hightower, Kendra E ^b   Malkakorpi, Susanna ^a   Musgrave, James R ^a   Neu, Margarete ^a   Rowland, Paul ^a   Shea, Robyn L ^a   Smith, Jeffery L ^b   Somers, Donald O ^a   Thomas, Sonia A ^b   Thompson, Gladstone ^a   Wang, Ruolan ^b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b GLAXOSMITHKLINE   (United States)

Author keywords

Inhibitor; JNK; JNK3; Kinase; MAPK; Selective

Indexed keywords

ADENOSINE TRIPHOSPHATE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 12; MITOGEN ACTIVATED PROTEIN KINASE P38; N (3 CYANO 4,5,6,7 TETRAHYDRO 1 BENZOTHIEN 2 YL)AMIDE; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; SYNAPTOPHYSIN; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CHEMICAL STRUCTURE; DRUG EFFICACY; DRUG POTENCY; HYDROGEN BOND; IC 50; X RAY CRYSTALLOGRAPHY;

AMIDES; BENZENE DERIVATIVES; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 10; MITOGEN-ACTIVATED PROTEIN KINASE 9; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33847000556     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.12.003     Document Type: Article

References (28)

1. Parang K., and Sun G. Curr. Opin. Drug Disc. Dev. 7 (2004) 617
2. Herlaar E., and Brown Z. Mol. Med. Today 5 (1999) 439
3. Manning A.M., and Davis R.J. Nat. Rev. Drug Disc. 2 (2003) 554
4. Liu G., and Rondinone C.M. Curr. Opin. Investig. Drugs 6 (2005) 979
5. Kuan C.-Y., Yang D.D., Roy D.R.S., Davis R.J., Rakic P., and Flavell R.A. Neuron 22 (1999) 667
6. Martin J.H., Mohit A.A., and Miller C.A. Mol. Brain Res. 35 (1996) 47
7. Resnick L., and Fennell M. Drug Discovery Today 9 (2004) 932
8. Kimberly W.T., Zheng J.B., Town T., Flavell R.A., and Selkoe D.J. J. Neurosci. 25 (2005) 5533
9. Swahn B.-M., Huerta F., Kallin E., Malmström J., Weigelt T., Viklund J., Womack P., Xue Y., and Öhberg L. Bioorg. Med. Chem. Lett. 15 (2005) 5095
10. Swahn B.-M., Xue Y., Arzel E., Kallin E., Magnus A., Plobeck N., and Viklund J. Bioorg. Med. Chem. Lett. 16 (2006) 1397
11. i = dissociation constant for inhibitor binding) of a potent inhibitor the anisotropy of the unbound fluorescent ligand is measurably different from the bound value. Truncated human JNK3 was expressed in baculovirus as a N-terminal His (6)-tagged fusion protein.[...].
12. Gewald K. Chem. Ber. 98 (1965) 3571
13. 11 p38α inhibitory activity data were generated using conditions previously described, see: Barker, M. D.; Hamblin, J. N.; Jones, K. L.; Patel, V. K.; Swanson, S.; Walker, A. L. Int. Patent Appl. WO 05/073232.
14. ERK2 kinase inhibitory activity was determined in a similar fashion to that described above for JNK3, using recombinant full length ERK2 expressed and purified as previously described, see:. McDonald O.B., Chen W.J., Ellis B., Hoffman C., Overton L., Rink M., Smith A., Marshall C.J., and Wood E.R. Anal. Biochem. 268 (1999) 318 The ERK2 used for the work described in this paper was not activated before or during the assay
15. 2 and 1 mM AMP-PNP. The crystals were grown at 10 °C, using the hanging drop vapour diffusion method, with a reservoir solution of 50 mM Tris/HCl, pH 7.2-7.6, 18-22% PEG3350 and 0.2 M KF and 1 μl + 1 μl hanging drops. JNK3t+MgAMP-PNP cocrystals were soaked at 20 °C in 50 mM Tris/HCl, pH 7.5, 20% PEG3350, and 0.2 M KF containing 0.8 mM inhibitor 5e for 4 days. The 8a complex was obtained in a similar way though crystals were soaked for 1 day in buffer (10 μL) containing 0.1 mg of solid 8a with 1 mM EDTA. Each crystal was cryoprotected by brief immersion into paratone-N (Hampton Research) prior to data collection. The PDB deposition codes for the 5e and 8a JNK3 complex crystal structures are 2O2U and 2O0U, respectively.
16. Xie X., Gu Y., Fox T., Coll J.T., Fleming M.A., Markland W., Caron P.R., Wilson K.P., and Su M.S.-S. Structure 6 (1998) 983
17. Adams J.L., Veal J., and Shewchuk L. In: Babine R.E., and Abdel-Meguid S.S. (Eds). Protein Crystallography in Drug Discovery (2004), Wiley-VCH, Weinheim Chapter 2
18. Bruno I.J., Cole J.C., Lommerse J.P.M., Rowland R.S., Taylor R., and Verdonk M.L. J. Comput. Aided Mol. Des. 11 (1997) 525
19. Abraham M.H. Chem. Soc. Rev. 22 (1993) 73
20. Le Questel J.-Y., Berthelot M., and Laurence C. J. Phys. Org. Chem. 13 (2000) 347
21. Liu C., Wrobleski S.T., Lin J., Ahmed G., Metzger A., Wityak J., Gillooly K.M., Shuster D.J., McIntyre K.W., Pitt S., Shen D.R., Zhang R.F., Zhang H., Doweyko A.M., Diller D., Henderson I., Barrish J.C., Dodd J.H., Schieven G.L., and Leftheris K. J. Med. Chem. 48 (2005) 6261
22. Allen F.H., Bird C.M., Rowland R.S., and Raithby P.R. Acta Crystallogr., Sect. B B53 (1997) 696
23. Wennmohs F., Staemmler V., and Schindler M. J. Chem. Phys. 119 (2003) 3208
24. Traxler P., and Furet P. Pharmacol. Ther. 82 (1999) 195
25. Scapin G., Patel S.B., Lisnock J., Becker J.W., and LoGrasso P.V. Chem. Biol. 10 (2003) 705
26. Wang Z., Canagarajah B.J., Boehm J.C., Kassisà S., Cobb M.H., Young P.R., Abdel-Meguid S., Adams J.L., and Goldsmith E.J. Structure 6 (1998) 1117
27. The ability of 5c at 10 μM concentration to displace the fusion protein from immobilised ATP-site probe ligands was determined as previously described, see:. Fabian M.A., Biggs III W.H., Treiber D.K., Atteridge C.E., Azimioara M.D., Benedetti M.G., Carter T.A., Ciceri P., Edeen P.T., Floyd M., Ford J.M., Galvin M., Gerlach J.L., Grotzfeld R.M., Herrgard S., Insko D.E., Insko M.A., Lai A.G., Lélias J.-M., Mehta S.A., Milanov Z.V., Velasco A.M., Wodicka L.M., Patel H.K., Zarrinkar P.P., and Lockhart D.J. Nat. Biotechnol. 23 (2005) 329
28. 33P]ATP (45 μM). For further details, see: www.upstate.com.